Profile data is unavailable for this security.
About the company
Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.
- Revenue in EUR (TTM)829.51m
- Net income in EUR170.34m
- Incorporated1946
- Employees2.11k
- LocationLaboratorios Farmaceuticos ROVI SAC/ Julian Camarillo, 35MADRID 28037SpainESP
- Phone+34 913756230
- Fax+34 913047881
- Websitehttps://www.rovi.es/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MorphoSys AG | 203.50m | -456.34m | 2.57bn | 464.00 | -- | -- | -- | 12.61 | -12.54 | -12.65 | 5.79 | -6.95 | 0.1002 | 1.86 | 4.58 | 388,358.00 | -22.47 | -10.25 | -27.58 | -11.61 | 83.89 | 85.92 | -224.25 | -78.53 | 1.38 | -- | -- | -- | -14.37 | 25.53 | -25.60 | -- | 3.11 | -- |
| Camurus AB | 156.94m | 38.79m | 2.73bn | 218.00 | 70.67 | 11.99 | 68.24 | 17.40 | 7.79 | 7.79 | 31.75 | 45.91 | 0.8265 | 1.14 | 6.65 | 8,557,742.00 | 20.43 | -1.13 | 23.79 | -1.41 | 93.17 | 90.05 | 24.71 | -1.63 | 7.39 | -- | 0.0086 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| Virbac SA | 1.25bn | 121.30m | 3.04bn | 5.46k | 25.07 | 3.35 | 18.11 | 2.44 | 14.36 | 14.36 | 147.65 | 107.57 | 0.894 | 1.30 | 7.94 | 228,412.00 | 8.65 | 8.70 | 12.12 | 12.44 | 64.93 | 65.61 | 9.67 | 10.21 | 1.08 | 18.05 | 0.1166 | 7.21 | 2.53 | 7.49 | -0.5289 | 43.26 | 12.08 | -- |
| Dottikon ES Holding AG | 342.05m | 87.14m | 3.78bn | 694.00 | 42.80 | 4.37 | 34.85 | 11.05 | 6.24 | 6.24 | 24.49 | 61.10 | 0.3135 | 0.6339 | 5.39 | 498,861.30 | 7.99 | 7.48 | 9.58 | 8.48 | 67.58 | 78.94 | 25.48 | 22.35 | 1.65 | 101.25 | 0.1062 | -- | 26.80 | 15.09 | 47.94 | 27.70 | 30.78 | -- |
| Siegfried Holding AG | 1.29bn | 113.32m | 4.09bn | 3.93k | 34.13 | 4.54 | 20.86 | 3.18 | 26.28 | 26.28 | 298.23 | 197.49 | 0.6958 | 2.27 | 3.14 | 323,288.60 | 6.17 | 6.51 | 7.67 | 7.98 | 25.20 | 23.24 | 8.86 | 9.06 | 1.39 | 7.93 | 0.3468 | 15.26 | 3.41 | 9.87 | -28.16 | 18.34 | 17.95 | 6.72 |
| Krka d.d. Novo Mesto | 1.83bn | 323.81m | 4.16bn | 11.80k | 12.12 | 1.74 | 9.77 | 2.27 | 10.48 | 10.48 | 59.36 | 73.17 | 0.6528 | 1.37 | 3.57 | 157,225.70 | 11.51 | 12.64 | 13.68 | 15.12 | 55.99 | 57.29 | 17.64 | 18.71 | 2.88 | 66.70 | 0.0056 | 59.21 | 5.18 | 6.28 | -13.58 | 12.45 | 8.35 | 18.57 |
| ALK-Abello A/S | 662.21m | 74.38m | 4.21bn | 2.83k | 62.19 | 7.31 | 36.85 | 6.35 | 2.49 | 2.49 | 21.93 | 21.19 | 0.752 | 1.29 | 5.81 | 1,749,646.00 | 8.45 | 3.50 | 10.36 | 4.37 | 63.25 | 60.66 | 11.23 | 5.07 | 1.23 | 50.27 | 0.0995 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
| Richter Gedeon Vegyeszeti Gyar Nyrt | 2.07bn | 486.59m | 4.47bn | 11.60k | 9.07 | 1.43 | 7.19 | 2.16 | 1,020.54 | 1,020.53 | 4,335.98 | 6,494.05 | 0.5724 | 1.46 | 4.05 | 68,856,070.00 | 13.62 | 11.64 | 15.34 | 13.28 | 67.11 | 58.18 | 23.80 | 18.93 | 3.08 | -- | 0.0153 | 39.67 | 0.2993 | 12.57 | -6.05 | 35.06 | 15.59 | 33.38 |
| Laboratorios Farmaceuticos ROVI SA | 829.51m | 170.34m | 4.86bn | 2.11k | 28.10 | 8.65 | 25.42 | 5.86 | 3.20 | 3.20 | 15.58 | 10.41 | 0.9883 | 1.04 | 5.13 | 392,946.00 | 20.29 | 18.90 | 28.88 | 25.58 | 59.35 | 59.82 | 20.53 | 20.13 | 0.8575 | -- | 0.1075 | 33.60 | 1.44 | 22.30 | -14.69 | 56.93 | 15.84 | 69.11 |
| Zealand Pharma A/S | 46.14m | -99.01m | 5.06bn | 270.00 | -- | 13.24 | -- | 109.74 | -12.52 | -12.52 | 5.78 | 45.56 | 0.1397 | 4.18 | 2.86 | 1,360,664.00 | -29.99 | -42.74 | -32.82 | -50.24 | 90.07 | 96.13 | -214.60 | -464.66 | 12.28 | -- | 0.1206 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
| Hikma Pharmaceuticals Plc | 2.66bn | 175.72m | 5.11bn | 8.97k | 29.13 | 2.51 | 14.43 | 1.92 | 0.6734 | 0.6734 | 10.18 | 7.83 | 0.6284 | 1.76 | 3.67 | 252,517.10 | 4.20 | 8.19 | 5.72 | 11.30 | 48.94 | 50.29 | 6.68 | 13.77 | 0.9029 | 7.68 | 0.3503 | 36.71 | 14.22 | 6.73 | 1.06 | -7.59 | 7.97 | 14.03 |
| Orion Oyj | 1.22bn | 216.80m | 5.32bn | 3.70k | 24.30 | 7.47 | 20.13 | 4.36 | 1.55 | 1.55 | 8.71 | 5.04 | 0.8866 | 1.57 | 6.01 | 336,013.20 | 15.73 | 19.47 | 21.38 | 24.16 | 55.10 | 59.38 | 17.74 | 20.71 | 1.00 | 74.43 | 0.2157 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
| DiaSorin SpA | 1.15bn | 159.85m | 5.50bn | 3.23k | 34.30 | 3.41 | 18.63 | 4.79 | 2.87 | 2.87 | 21.49 | 28.83 | 0.3469 | 1.31 | 5.49 | 355,153.10 | 4.79 | 10.30 | 5.32 | 11.50 | 64.55 | 66.70 | 13.80 | 21.25 | 2.08 | 11.35 | 0.4368 | 24.71 | -15.64 | 11.40 | -33.65 | 0.2167 | 16.49 | -- |
| Grifols SA | 6.59bn | 59.31m | 5.60bn | 23.74k | 101.52 | 1.07 | 8.99 | 0.8493 | 0.0901 | 0.0901 | 9.80 | 8.58 | 0.3068 | 1.23 | 9.86 | 277,627.00 | 0.8408 | 2.39 | 1.06 | 3.04 | 37.84 | 40.26 | 2.74 | 7.54 | 1.29 | 1.56 | 0.5593 | -- | 8.71 | 8.00 | -71.52 | -36.98 | -0.8127 | -- |
| BACHEM HOLDING AG | 583.84m | 113.12m | 6.57bn | 2.01k | 57.80 | 4.92 | 41.38 | 11.26 | 1.50 | 1.50 | 7.73 | 17.61 | 0.3765 | 1.23 | 3.33 | 287,794.60 | 7.29 | 8.85 | 8.17 | 10.28 | 30.65 | 31.63 | 19.38 | 19.74 | 3.04 | 29.80 | 0.0003 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
Data as of May 23 2024. Currency figures normalised to Laboratorios Farmaceuticos ROVI SA's reporting currency: Euro EUR
9.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 1.13m | 2.08% |
| T. Rowe Price International Ltd.as of 31 Mar 2024 | 862.55k | 1.60% |
| The Vanguard Group, Inc.as of 09 May 2024 | 780.64k | 1.45% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 549.97k | 1.02% |
| Santander Private Banking Gestion SA SGIICas of 31 Dec 2023 | 498.88k | 0.92% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 346.54k | 0.64% |
| ProfitlichSchmidlin AGas of 31 Jan 2024 | 319.00k | 0.59% |
| Victory Capital Management, Inc. (Investment Management)as of 29 Feb 2024 | 286.48k | 0.53% |
| Wellington Management International Ltd.as of 30 Jun 2023 | 279.88k | 0.52% |
| Invesco Asset Management Ltd.as of 29 Feb 2024 | 256.17k | 0.47% |
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
